Consolidative Renal Cell Carcinoma Metastatectomy for Partial Response After Multitargeted Tyrosine Kinase Inhibitor Therapy

Urology

Volumn 70, Issue 1, 2007, Pages 178.e9-178.e11

  Neill, Mischel G ^a   Wei, Alice C ^a   Jewett, Michael A S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INTERLEUKIN 2; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; METASTASIS; METASTATECTOMY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PHLEGMON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 34447531755     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.044     Document Type: Article

References (9)

1. Cohen H.T., and McGovern F.J. Renal cell carcinoma. N Engl J Med 353 (2005) 2477-2490
2. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
3. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 23 (2005) 380s
4. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
5. Strumberg D., Awada A., Hirte H., et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rash associated with outcome?. Eur J Cancer 42 (2006) 548-556
6. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
7. Lillemoe K.D., Kaushal S., Cameron J.L., et al. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg 229 (1999) 693-700
8. Suzuki Y., Tanioka Y., Hori Y., et al. Randomized controlled trial of ultrasonic detector or conventional division in distal pancreatectomy for non-fibrotic pancreas. Br J Surg 86 (1999) 608-611
9. Ridgeway M.G., and Stabile B.E. Surgical management and treatment of pancreatic fistulas. Surg Clin N Am 76 (1996) 1159-1173